GIVING LIFE TO SCIENCE®

We are dedicated to giving life to science and transforming innovation into value

Strong track record of clinical success
6 x
Better probability of clinical success compared to the industry average1
80 %
Clinical trial success rate2
3
Taken from inception at PureTech to U.S. Food and Drug Administration approval
Unlocking the Potential of Validated Efficacy

We do this by enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine

News & Press

Press releases
2026-10-26
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
Press releases
2026-10-19
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

1 Industry average data measures the probability of clinical trial success of therapeutics by calculating the number of programs progressing to the next phase vs. the number progressing and suspended (Phase 1=52%, Phase 2=29%, Phase 3=58%). BIO, PharmaIntelligence, QLS (2021) Clinical Development Success Rates 2011 -2020. This study did not include therapeutics regulated as devices.
2 The percentage includes number of successful trials out of all trials run for all therapeutic candidates advanced through at least Phase 1 by PureTech or its historical Founded Entities from 2009 onward.